ANDA Litigation Settlements

Spring 2018

GENERICally Speaking: A Hatch Waxman Litigation Bulletin
Case Name Drug Patent No(s). Publicly Available Terms
Forest Labs., LLC v. Sun Pharma Global FZE, 17-0865 (D. Del.) Linzess® (linaclotide capsules) 8,933,030 Sun Pharma will be able to sell its generic linaclotide product in February 2031, six months before the expiration of the patent-in-suit.
Boehringer Ingelheim Pharma GMBH & Co. KG v. Teva Pharms. USA, Inc., 14-7811 (D.N.J.) Pradaxa® (dabigatran etexilate mesylate capsules) 6,087,380 Mylan agreed that the patent-in-suit is valid and further agreed to delay launching its ANDA product.
Allergan, Inc. v. Innopharma, Inc., 15-1504 (E.D. Tex.) Restasis® (cyclosporine ophthalmic emulsion) 8,629,111
8,633,162
8,642,556
8,648,048
8,685,930
9,248,191
InnoPharma will be allowed to market its generic version of Restasis in February 2024 or possibly earlier. InnoPharma may also be allowed to launch an authorized generic version of the drug with Allergan as the supplier in August 2024.
Pernix Ireland Pain Ltd. v. Actavis Labs. FL, Inc., 16-0138 (D. Del.) Recro Gainesville LLC v. Actavis Labs. FL, Inc., 17-1535 (D. Del.) Recro Gainesville LLC v. Actavis Labs. FL, Inc., 17-1822 (Fed. Cir.) Zohydro® (hydrocodone bitartrate extended-release capsules) 9,265,760
9,326,982
9,333,201
9,339,499
9,421,200
9,433,619
6,228,398
6,902,742
9,132,096
9,713,611

Actavis will be able to launch its generic hydrocodone drug in March 2029.

Related Publications

Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top